An improved LC-MS/MS method for the determination of taspoglutide in plasma and urine using orthogonal HILIC-RP column switching, ultra-performance LC separation and 'wrong-way-round' electrospray ionization

Biomedical Chromatography

Volumn 25, Issue 11, 2011, Pages 1215-1221

  Heinig, Katja ^a   Wirz, Thomas ^a   Yuan, Moucun ^b   Tingler, Michael ^b   Mylott, William ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Pharmaceutical Product Development   (United States)

Author keywords

Column switching; HILIC; LC MS MS; Taspoglutide; Wrong way round ionization

Indexed keywords

BODY FLUIDS; COLUMN CHROMATOGRAPHY; HYDROPHILICITY; MASS SPECTROMETRY; PHASE SEPARATION; SIGNAL TO NOISE RATIO;

COLUMN SWITCHING; HILIC; LC-MS-MS; LC.MS/MS; LOWER LIMITS OF QUANTITATIONS; PEPTIDE DRUGS; SYNTHETIC PEPTIDE; TASPOGLUTIDE; ULTRA-PERFORMANCE LC; WRONG-WAY-ROUND IONIZATION;

ELECTROSPRAY IONIZATION;

FORMIC ACID; SURFACTANT; TASPOGLUTIDE; PEPTIDE;

ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; ISOTOPE LABELING; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; NONHUMAN; PLASMA; PRECIPITATION; REPRODUCIBILITY; SIGNAL NOISE RATIO; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS; BLOOD; CHEMICAL PHENOMENA; CHEMISTRY; DRUG STABILITY; PROCEDURES; SENSITIVITY AND SPECIFICITY; URINE;

ANIMALIA;

CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PEPTIDES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 79959444199     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1593     Document Type: Article

References (20)

1. Antia FD and Horvath C. High performance liquid chromatography at elevated temperatures: examination of conditions for the rapid separation of large molecules. Journal of Chromatography 1988; 435: 1-l5.
2. Arjona A. Taspoglutide. Drugs of the Future 2008; 33: 938-943.
3. Chambers E, Wagrowski-Diehl DM, Lu Z and Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. Journal of Chromatography B 2007; 352: 22-34.
4. Chen C, Bajpai L, Mollovaa N and Leung K. Sensitive and cost-effective LC-MS/MS method for quantitation of CVT-6883 in human urine using sodium dodecylbenzenesulfonate additive to eliminate adsorptive losses. Journal of Chromatography B 2009; 877: 943-947.
5. FDA. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001; 1-25.
6. Guillarme D, Schappler J, Rudaz S and Veuthey JL. Coupling ultra-high-pressure liquid chromatography with mass spectrometry. Trends in Analytical Chemistry 2010; 29: 15-27.
7. Heinig K and Wirz T. Determination of taspoglutide in human and animal plasma using liquid chromatography - tandem mass spectrometry with orthogonal column-switching. Analytical Chemistry 2009; 81: 3705-3713.
8. Heinisch S and Rocca JL. Sense and nonsense of high-temperature liquid chromatography. Journal of Chromatography A 2009; 1216: 642-658.
9. Jemal M, Ouyang Z and Xia YQ. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. Biomedical Chromatography 2010; 24: 2-19.
10. John H, Walden M, Schäfer S, Genz S and Forssmann WG. Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry 2004; 378: 883-897.
11. Kapitza C, Heise T, Birman P, Jallet K, Ramis J and Balena R. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabetic Medicine 2009; 26: 1156-1164.
12. Mansoori BA, Volmer DA and Boyd RK. 'Wrong-way-round' electrospray ionization of amino acids. Rapid Communications in Mass Spectrometry 1997; 11: 1120-1130.
13. Mazzeo JR, Neue UD, Kele M and Plumb RS. Advancing liquid chromatography performance with smaller particles and higher pressure. Analytical Chemistry 2005; 77: 460-467.
14. Norden AGW, Lapsley M, Lee PJ, Pusey CD, Scheinman SJ, Tam FWK, Thakker RV, Unwin RJ and Wrong O. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney International 2001; 60: 885-1892.
15. Peng L and Farkas T. Analysis of basic compounds by reversed-phase liquid chromatography-electrospray mass spectrometry in high-pH mobile phases. Journal of Chromatography A 2008; 1179: 131-144.
16. Stokvis E, Rosing H, López-Lázaro L, Rodriguez I, Jimeno JM, Supko JG, Schellens JHM and Beijnen JH. Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. Journal of Mass Spectrometry 2002; 37: 992-1000.
17. Timm U, Wall M and Dell D. A new approach for dealing with the stability of drugs in biological fluids. Journal of Pharmaceutical Sciences 1985; 74: 972-977.
18. van den Broek I, Sparidans RW, Schellens JHM and Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. Journal of Chromatography B 2008; 872: 1-22.
19. Van Uytfanghe K, Rodriguez-Cabaleiro D, Stoeckl D and Thienpont LM. New liquid chromatography/electrospray tandem mass spectrometry measurement procedure for quantitative analysis of human insulin in serum. Rapid Communications in Mass Spectrometry 2007; 21: 819-821.
20. Vishwanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG and Weiner R. Workshop/conference report - quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS Journal 2007; 9: E30-42.